GlassScriptPhysician profile
Bradley G Goldberg
NPI 1447348826
$2,044.53
in general payments reported to CMS, 2019-2025
26 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $70.11 · 2021: $319 · 2022: $182 · 2023: $456 · 2024: $372 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.52 | 2019-2025 | |
| Hologic Sales and Service, LLC | $303.57 | 2019-2025 | Aptima, Fluent Fluid Management System, Novasure |
| Astellas Pharma US INC | $251.28 | 2021-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $146.62 | 2023-2025 | Myfembree, Gemtesa |
| Corcept Therapeutics | $115.00 | 2025 | Korlym |
| Myriad Women'S Health, INC. | $114.75 | 2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $110.16 | 2024 | Lokelma |
| Amgen INC. | $77.27 | 2021-2024 | Krystexxa |
| Allergan, INC. | $59.76 | 2019 | |
| Roche Diagnostics Corporation | $57.06 | 2019-2021 | |
| Pfizer INC. | $56.91 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.28 | 2021-2022 | |
| Organon LLC | $45.19 | 2022-2023 | Nexplanon |
| Biogen, INC. | $44.79 | 2025 | Zurzuvae |
| Daiichi Sankyo INC. | $33.46 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $31.44 | 2024 | |
| Coloplast Corp | $26.62 | 2019 | |
| Aspira Women'S Health INC | $25.10 | 2021 | |
| Becton, Dickinson and Company | $18.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.08 | 2025 | |
| Merck Sharp & Dohme LLC | $15.19 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.80 | 2019 | |
| Millicent US INC | $13.58 | 2024 | Femring, Intrarosa |
| Smith+Nephew, INC. | $12.63 | 2019 | |
| Agile Therapeutics, INC. | $12.38 | 2021 | |
| Minerva Surgical, INC | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.